Explore data for an FDA-approved treatment option in HR+, HER2- breast cancer in certain adjuvant or metastatic settings

Name: Explore data for an FDA-approved treatment option in HR+, HER2- breast cancer in certain adjuvant or metastatic settings
Start: 2022-12-09T10:00:00-06:00
End: 2022-12-09T11:00:00-06:00

October 31, 2022